Positions

Overview

  • Introduction:

    Dr. Bal is a malignant hematologist caring for patients with plasma cell disorders with special interest in Light chain (AL) Amyloidosis and MultipleMyeloma. She is additionally sub-specialty fellowship trained to perform stem cell
    transplantation and cellular therapies such as chimeric antigen receptor (CAR) T cell therapies.

    Clinical Interests:

    Dr. Bal is working with other UAB subspecialty colleagues to start a specialized interdisciplinary program in systemic AL Amyloidosis, the first of its kind in Alabama.

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2022 Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. 2022
    2022 Disparities in clinical trial participation among older adults with multiple myeloma in the United States.  Journal of Geriatric Oncology.  13:1241-1243. 2022
    2022 Patterns of Utilization and Outcomes of Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements.  Clinical Lymphoma, Myeloma and Leukemia.  22:825-834. 2022
    2022 Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.  Journal of Clinical Oncology.  40:2901-2912. 2022
    2022 Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy.  American Journal of Hematology.  97:1170-1177. 2022
    2022 Pre-treatment neutrophil to lymphocyte ratio as a biomarker of frailty and predictor of survival among older adults with multiple myeloma.  Journal of Geriatric Oncology.  13:486-492. 2022
    2022 Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research 2022
    2022 Real-world applicability of commercial chimeric antigen receptor T-cell therapy among older adults with relapsed and/or refractory multiple myeloma.  American Journal of Hematology.  97:E153-E155. 2022
    2022 Revisiting the impact of immunoglobulin isotypes in multiple myeloma.  Annals of Hematology.  101:825-829. 2022
    2022 Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies.  Leukemia.  36:877-880. 2022
    2022 A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients.  Bone Marrow Transplantation.  57:295-298. 2022
    2022 Clinical implications of measurable residual disease assessment in multiple myeloma in the era of quadruplet therapy 2022
    2021 AL amyloidosis: untangling new therapies.  Hematology.  2021:682-688. 2021
    2021 Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myeloma.  British Journal of Haematology.  195:e113-e116. 2021
    2021 Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation.  American Journal of Hematology.  96:E396-E398. 2021
    2021 Autologous stem cell transplantation in the age of ANDROMEDA.  British Journal of Haematology.  193:865-866. 2021
    2021 Impact of access to care on 1-year mortality following allogeneic blood or marrow transplantation.  Bone Marrow Transplantation.  56:1364-1372. 2021
    2021 Maintaining the minimal: dynamics of measurable residual disease with continuous lenalidomide therapy.  Lancet Haematology.  8:e386-e387. 2021
    2021 Caution with Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma - Reply.  JAMA Oncology.  7:635-636. 2021
    2021 New regimens and directions in the management of newly diagnosed multiple myeloma.  American Journal of Hematology.  96:367-378. 2021
    2021 International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.  Leukemia.  35:18-30. 2021
    2020 Age is just a number, the wrong number.  Cancer.  126:5014-5016. 2020
    2020 Solid Organ Transplantation 2020
    2020 Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma.  Biology of Blood and Marrow Transplantation.  26:1394-1401. 2020
    2020 Assessment of measurable residual disease (MRD) in multiple myeloma: a review of the data.  Clinical advances in hematology & oncology : H&O.  18:3-10. 2020
    2020 Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma.  Clinical advances in hematology & oncology : H&O.  18:1-20. 2020
    2020 Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma: further observations.  Clinical advances in hematology & oncology : H&O.  18:17. 2020
    2020 Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients with High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis.  JAMA Oncology.  6:1759-1765. 2020
    2020 Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline Chemoimmunotherapy.  Biology of Blood and Marrow Transplantation.  2020
    2019 Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma.  British Journal of Haematology.  186:807-819. 2019
    2019 Lessons learned from checkpoint blockade targeting PD-1 in multiple myeloma.  Cancer Immunology Research.  7:1224-1229. 2019
    2016 The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic cancer 2016
    2015 Myocardial perfusion imaging determination using an appropriate use smartphone application..  Journal of Nuclear Cardiology.  22:66-71. 2015
    2014 Potential of F-18 PET/CT in the Detection of Leptomeningeal Metastasis..  The neuroradiology journal.  27:685-689. 2014
    2011 Long-term outcome of lobar ablation versus completion thyroidectomy in differentiated thyroid cancer..  Nuclear Medicine Communications.  32:52-58. 2011

    Principal Investigator On

    Investigator On

  • Plasma Cells in Health and Disease - Project 1: Epigenetic and Metabolic Mechanisms Governing Commitment to the Long-lived Plasma Cell Pool  awarded by Emory University
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by CAREVIVE SYSTEMS, INC.
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by SUTRO BIOPHARM
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by IONIS PHARMACEUTICALS, INC.
  • Private Grant  awarded by MARKER THERAPEUTICS INC
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by FATE THERAPEUTICS, INC.
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by MARKER THERAPEUTICS INC
  • Private Grant  awarded by EUSA PHARMA
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by Janssen
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by Amgen Foundation, Inc.
  • Private Grant  awarded by BRISTOL-MYERS SQUIBB COMPANY
  • UAB 1815: Phase 2 Trial of Intensive Chemo-immu,otherapy with Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Relapsed.Refractory Myeloma In the context of Salvage Autologous Hematopoietic Cell Transplantation  awarded by Memorial Sloan-Kettering Cancer Center

    • Education And Training

  • Bachelor of Medicine & Surgery (MBBS), Bharati Vidyapeeth University 2012

    • Full Name

  • Susan Bal